

*Use of Selective COX-2 Inhibitors for Chronic Therapy:
The Managed Care Perspective*

This supplement to *The American Journal of Managed Care* includes a continuing education article that has been peer reviewed by an expert in the field.

Activity Chair

James M. Scheiman, MD
Associate Professor of Medicine
Division of Gastroenterology
University of Michigan Medical Center
Ann Arbor, Michigan

Faculty

A. Mark Fendrick, MD
Associate Professor
Division of General Medicine
Department of Internal Medicine
Health Management and Policy
University of Michigan
Ann Arbor, Michigan

Marc C. Hochberg, MD, MPH
Professor of Medicine and Epidemiology and
Preventive Medicine
University of Maryland School of Medicine
Head, Division of Rheumatology and
Clinical Immunology
University of Maryland Medical Center
Baltimore, Maryland

DISCLOSURE STATEMENT

In accordance with ACCME *Standards for Commercial Support of Continuing Medical Education* and the HSC-CME *Disclosure Policy for CME Activities*, faculty members have been asked to disclose any relationship they may have with the commercial supporter of this CME activity or with companies providing drugs, medical equipment, etc, that may have relevance to the content of their manuscripts. Such disclosure is intended to provide participants with sufficient information to evaluate whether the content has been influenced by the faculty's relationship(s) or financial interests with said companies.

It is the policy of the Health Science Center for Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs. All faculty participating in continuing pharmaceutical education activities sponsored by the Health Science Center for Continuing Medical Education are required to disclose to the program audience any real or apparent conflict of interest related to the content of their presentations.

It is also the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

The following faculty have reported receiving something of value* from the commercial supporter of this activity or from a corporate organization whose product(s) may have relevance to the content of this supplement:

■ **Marc C. Hochberg, MD, MPH**

Research Grant Support From:

Arthritis Foundation
Aventis (Quintiles Transnational Corporation)
Department of Veterans Affairs
GlaxoSmithKline
Merck & Co, Inc
National Institutes of Health

Consultant To:

aaiPharma Inc
Abbott Laboratories
Aventis (Quintiles Transnational Corporation)
Bristol-Myers Squibb Company
Genzyme Corporation
Eli Lilly and Company
Merck & Co, Inc
NEGMA Laboratories
Novartis AG
Proctor & Gamble
Sanofi-Synthelabo Inc
Wyeth Pharmaceuticals

■ **A. Mark Fendrick, MD**

Research Grant Support From:

Merck & Co, Inc

Speakers' Bureau For:

Merck & Co, Inc
TAP

Consultant To:

AstraZeneca
Merck & Co, Inc
McNeil
Procter & Gamble
TAP

Received Honoraria From:

Merck & Co, Inc
TAP

■ **James M. Scheiman, MD**

Research Grant Support From:

AstraZeneca
BykGolden
Merck & Co, Inc
Pfizer Inc
SmithKlineBeecham

Speakers' Bureau For:

AstraZeneca
Merck & Co, Inc
Pfizer Inc
TAP
Wyeth

Consultant To:

AstraZeneca
Merck & Co, Inc
McNeil
Nitromed

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

*Something of value refers to any equity position, receipt of royalties/honoraria, funding of a research grant, consultancy agreements, or to any other relationship with a company that provides sufficient reason for disclosure.

Disclosure of Discussions of Off-Label and/or Investigational Use of Pharmaceutical Products

This activity includes discussions of data from a recent trial on the use of rofecoxib in which some patients had rheumatoid arthritis. Physicians should note that these are not currently FDA-approved indications for these products and are advised to consult current prescribing information for FDA-approved indications.

The opinions expressed are those of the authors and all materials have been included with their permission.